Calcipotriol zur Prävention der Polymorphen Lichtdermatose - Calcipotriol und PLD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-000626-39-AT

Enrollment

Registered

2008-07-14

Start date

2008-08-28

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polymorphic light eruption MedDRA version: 9.1 Level: LLT Classification code 10036087 Term: Polymorphic light eruption

Interventions

Trade Name: Psorcutan cream Pharmaceutical Form: Cream INN or Proposed INN: Psorcutan Creme Pharmaceutical form of the placebo: Cream Route of administration of the placebo: Cutaneous use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Polymorphous light eruption Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: skin cancer, malignant melanoma, multiple dysplastc nevi, photosensitive disorders, autoimmune diseases, therapy with immunosuppressive drugs, liver or renal diseases, pregnancy and nursing,

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the efficacy of a pretreatment with calcipotriol in polymorphic light eruption.;Secondary Objective: ;Primary end point(s): PLD Score	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026